Against a background of a rapidly evolving treatment landscape, a contemporary, evidence‐
based consolidated understanding of mortality in people with congenital hemophilia A …

Introduction Improvements in haemophilia treatment over the last decades resulted in
increased life expectancy in persons with haemophilia (PWH). Aim We conducted a …

Introduction Brazil has the fourth largest world population of patients with haemophilia.
However, mortality rates in this population are unknown. Aim To analyse mortality and its …

Hemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the
F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting …

Gene therapy is an opportunity for haemophilia patients to receive a one‐time treatment and
have lasting factor levels for years or decades instead of dependence on repeated …

Bleeding disorders, including hemophilia, can be seen in every ethnic population in the
world. Among various bleeding disorders, reduced bone density has been addressed in …

Background Rare bleeding disorders include inherited coagulation disorders except for von
Willebrand disease and hemophilia A and B. These disorders affect both men and women …

Introduction Haemophilia is a well‐known bleeding disorder that affects people worldwide.
The main therapeutic strategy is regular infusion of exogenous factor VIII to ensure an …

Background: Hemophilia is a congenital bleeding disorder with X-linked inheritance that is
associated with a deficiency of coagulation factor 8 (hemophilia A) or 9 (hemophilia B). The …

In an attempt to distinguish between ALL, CML, CLL, AML, ITP, DIC, hemophilia A,
hemophilia B, von Willebrand disease, Microangiopathic Hemolytic Anemia, Bernard …